Viking Global Investors
TXG icon

Viking Global Investors’s 10x Genomics TXG Stock Holding History

Viking Global Investors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-71,069
Closed -$3.58M – 77
2019
Q3 		$3.58M Buy
+71,069
New +$3.93M 0.02% 61

Other funds holding TXG

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Viking Global Investors's TXG Position: Q4 2019 in Review

Viking Global Investors sold out of 10x Genomics (TXG) in Q4 2019, closing a stake of 71,069 shares — an estimated $3.58M sold.

Viking Global Investors first reported a position in TXG in Q3 2019 and held it in 1 quarter. The position peaked at $3.58M in Q3 2019. 85 funds tracked by Wall St. Rank hold TXG as of Q4 2019.

  • Viking Global Investors reported no remaining 10x Genomics position as of Q4 2019 after selling out during the quarter.
  • Viking Global Investors sold 71,069 10x Genomics shares in Q4 2019, an estimated $3.58M.
  • Viking Global Investors first reported a position in 10x Genomics in Q3 2019 and held it in 1 quarter.
  • Viking Global Investors's 10x Genomics position peaked at $3.58M in Q3 2019.
  • 85 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2019.

Based on Viking Global Investors's 13F filing for Q4 2019, filed 13 Feb 2020.